PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.

Tang, Monica

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. [electronic resource] - Gynecologic oncology 09 2019 - 531-538 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1095-6859

10.1016/j.ygyno.2019.06.011 doi


Adult
Aged
Anastrozole--adverse effects
Antineoplastic Agents, Hormonal--adverse effects
Carcinoma, Ovarian Epithelial--drug therapy
Cystadenocarcinoma, Serous--drug therapy
Female
Humans
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local--drug therapy
Ovarian Neoplasms--drug therapy
Postmenopause
Progression-Free Survival
Prospective Studies
Quality of Life
Receptors, Estrogen--metabolism
Receptors, Progesterone--metabolism
Young Adult